{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:56:11Z","timestamp":1792281371697,"version":"4.4.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2020,12,17]]},"abstract":"<jats:p>Cefiderocol (formerly S-649266) is a novel siderophore-conjugated cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli. The siderophore component binds iron and uses active iron transport for drug entry into the bacterial periplasmic space. The cephalosporin moiety is the active antimicrobial component, structurally resembling a hybrid between ceftazidime and cefepime. Like other \u03b2-lactam agents, the principal bactericidal activity of cefiderocol occurs via inhibition of bacterial cell wall synthesis by binding of penicillin-binding proteins (PBPs) and inhibiting peptidoglycan synthesis, leading to cell death.<\/jats:p>","DOI":"10.1128\/jcm.00951-20","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T10:45:55Z","timestamp":1596105955000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":158,"title":["Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?"],"prefix":"10.1128","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6134-151X","authenticated-orcid":false,"given":"Patricia J.","family":"Simner","sequence":"first","affiliation":[{"name":"Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.304"},{"key":"e_1_3_3_3_2","unstructured":"O'Neil J. 2016. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance."},{"key":"e_1_3_3_4_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz830"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1426745"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"e_1_3_3_8_2","unstructured":"European Medicine Company. 2020. Fetcroja. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja#overview-section. Accessed July 2020."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00256-20"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz825"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.03.011"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv402"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.007"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.10.007"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01695-15"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"e_1_3_3_20_2","unstructured":"Shionogi Inc. 2019. Cefiderocol FDA briefing document. https:\/\/www.fda.gov\/media\/131703\/download."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa117"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115012"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0298"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01649-20"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-17"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Ito A Nishikawa Ishii R Kuroiwa M Kurihara N Sakikawa I Ota T Rokushima M Tsuiji M Sato T Yamano Y. 2018. Mechanisms of cefiderocol high MIC mutants obtained in non-clinical studies abstr 696. IDWeek 2018 San Francisco CA.","DOI":"10.1093\/ofid\/ofy210.703"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00198-20"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00966-20"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01405-16"},{"key":"e_1_3_3_30_2","volume-title":"June, 2017 AST agenda summary minutes","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. June, 2017 AST agenda summary minutes. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_31_2","volume-title":"Performance standards for antimicrobial susceptibility testing; thirtieth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; thirtieth informational supplement. M100-S30. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.03.003"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2011.518"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5102-5108.2004"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1988.tb02907.x"},{"key":"e_1_3_3_36_2","volume-title":"June, 2019 AST agenda summary minutes","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. June, 2019 AST agenda summary minutes. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_37_2","unstructured":"Centers for Disease Control and Prevention. 2020. CDC & FDA Antibiotic Resistance (AR) Isolate Bank. CDC Atlanta GA. Accessed 30 April 2020."},{"key":"e_1_3_3_38_2","unstructured":"EUCAST. 2020. Breakpoints for cefiderocol from EUCAST. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Cefiderocol_addendum_20200501.pdf."},{"key":"e_1_3_3_39_2","unstructured":"U.S. Food and Drug Administration. 2019. Cefiderocol injection. https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection. Accessed 13 February 2020."},{"key":"e_1_3_3_40_2","unstructured":"Food and Drug Administration Center for Drug Center for For Drug Evaluation and Research. 2019. Final summary minutes of the Antimicrobial Drugs Advisory Committee Meeting. https:\/\/www.fda.gov\/media\/133853\/download. Accessed July 2020."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00951-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00951-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T07:26:05Z","timestamp":1646465165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00951-20"}},"subtitle":[],"editor":[{"given":"Carey-Ann D.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,17]]}},"alternative-id":["10.1128\/JCM.00951-20"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00951-20","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"assertion":[{"value":"2020-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00951-20"}}